Targets › TERT
4 programs from 4 companies in 6 trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Hematology; next expected readout Feb 2027.
Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. (UniProt, O14746)
Open in Phaseline: the race on TERT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Geron | Imetelstat sodium Telomerase reverse transcriptase inhibitor | TERT | Phase 3 | Myelofibrosis; Myelodysplastic Syndromes | Feb 2027 |
| Assistance Publique - Hôpitaux de Paris | Cancer vaccine against TERT and PTPRZ1 Cancer vaccine targeting glioma-associated antigens (TERT and PTPRZ1) | TERT, PTPRZ1 | Phase 1 | Newly Diagnosed Glioblastoma | Mar 2028 |
| Children's Oncology Group | Imetelstat Telomerase reverse transcriptase inhibitor | TERT | Phase 1 | Recurrent Childhood Acute Myeloid Leukemia | Mar 2028 |
| Douglas Tremblay | Imetelstat Telomerase reverse transcriptase inhibitor | TERT | Phase 1 | Relapsed Acute Myeloid Leukemia | Jun 2030 |
Myelofibrosis (2) Relapsed Acute Myeloid Leukemia (1) Newly Diagnosed Glioblastoma (1) Myelodysplastic Syndromes (1) Recurrent Childhood Acute Myeloid Leukemia (1)
small molecule (2), protein or peptide (1), mixed (1)
Douglas Tremblay (1) Assistance Publique - Hôpitaux de Paris (1) Geron (1) Children's Oncology Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.